Swedbank AB Buys 54,360 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Swedbank AB lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,101,969 shares of the biopharmaceutical company’s stock after acquiring an additional 54,360 shares during the period. Swedbank AB owned approximately 0.17% of Gilead Sciences worth $194,159,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Strategic Blueprint LLC increased its stake in Gilead Sciences by 7.5% in the fourth quarter. Strategic Blueprint LLC now owns 2,750 shares of the biopharmaceutical company’s stock valued at $254,000 after acquiring an additional 192 shares during the last quarter. Asset Dedication LLC raised its holdings in shares of Gilead Sciences by 43.3% during the 4th quarter. Asset Dedication LLC now owns 6,421 shares of the biopharmaceutical company’s stock worth $593,000 after buying an additional 1,940 shares in the last quarter. Twelve Points Wealth Management LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth $611,000. SteelPeak Wealth LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at about $4,921,000. Finally, Mayflower Financial Advisors LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth about $317,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Up 1.9 %

Shares of Gilead Sciences stock traded up $1.76 during midday trading on Wednesday, reaching $95.61. 666,882 shares of the company’s stock traded hands, compared to its average volume of 6,498,963. The company has a market cap of $119.16 billion, a PE ratio of 1,058.96, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The stock has a 50 day moving average of $92.00 and a 200-day moving average of $85.44. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the previous year, the firm posted $2.29 EPS. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Analysts Set New Price Targets

GILD has been the subject of a number of recent research reports. BMO Capital Markets upped their target price on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Sanford C. Bernstein initiated coverage on Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target for the company. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Barclays upped their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.